What is Sudo Biosciences?
Founded in 2020 and headquartered in Menlo Park, California, Sudo Biosciences operates as a high-growth biopharmaceutical entity. The company is dedicated to the discovery and development of novel therapeutics, leveraging advanced scientific methodologies to address complex disease states. By focusing on high-impact areas of medical research, Sudo Biosciences has established itself as a key player in the biotech sector, attracting interest from top-tier institutional investors and corporate venture arms alike. Its market position is defined by a commitment to rigorous clinical validation and the pursuit of transformative patient care solutions.
How much funding has Sudo Biosciences raised?
Sudo Biosciences has raised a total of $184M across 2 funding rounds:
Series A
$37M
Series B
$147M
Series A (2022): $37M, investors not publicly disclosed
Series B (2024): $147M led by Enavate Sciences, Frazier Life Sciences Management, TPG, Surveyor Capital, Sanofi Ventures, Eventide Asset Management, and Dementia Discovery Fund
Key Investors in Sudo Biosciences
Enavate Sciences
Enavate Sciences is committed to invest in and support the strategic growth of innovative therapeutic and enabling technology companies that have the potential to transform patient care and improve quality of life.
Frazier Life Sciences Management
Frazier Life Sciences is a longstanding biotech investment firm that employs both venture and public strategies to partner with and build companies focused on developing novel therapeutics.
TPG
TPG is a global alternative asset management firm founded in 1992 with investment strategies spanning private equity, growth equity, impact investing, real estate, market solutions and credit.
What's next for Sudo Biosciences?
With the successful completion of this major strategic investment, Sudo Biosciences is poised to transition into a more intensive phase of clinical development. The capital will likely be deployed to advance its lead candidates through the regulatory pipeline and expand its internal research capabilities. As the company scales, the focus will remain on maintaining its competitive edge in the biopharmaceutical market, potentially exploring new therapeutic modalities and strengthening its intellectual property portfolio. The involvement of seasoned investors suggests a long-term strategy aimed at achieving significant clinical milestones and potentially positioning the firm for future strategic partnerships or public market entry.
See full Sudo Biosciences company page
